CD 44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer

Affiliations: Department of Immunology, School of Medicine, Konkuk University, Chungju, South Korea Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea Department of Bioscience and Biotechnology, Sejong University, Seoul, South Korea Department of Gynecologic Oncology & Reproductive Medicine, Center for RNAi and Non-coding RNA and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA These authors contributed equally to this work. These authors shared senior authorship of this article.